

# WRHA HAZARDOUS MEDICATIONS LIST<sup>1</sup>

CYTOTOXIC HAZARDOUS MEDICATIONS			
ado-trastuzumab emtansine	dabrafenib	ibrutinib	raltitrexed
afatinib	dacarbazine	IDArubicin	regorafenib
altretamine	DACTINomycin	ifosfamide	romidepsin
amsacrine	dasatinib	imatinib <sup>2</sup>	ruxolitinib
arsenic	DAUNOrubicin	irinotecan	
axitinib	deferiprone		SORAFenib
azaCITIDine	dexrazoxane	lapatinib	streptozocin
azaTHIOprine <sup>2</sup>	DOCEtaxel	lenalidomide	SUNItinib
	DOXOrubicin	lomustine	
bendamustine			temozolomide
bleomycin	epirubicin	mechlorethamine	temsirolimus
bortezomib	eribulin	melphalan	teniposide
bosutinib	erlotinib <sup>2</sup>	mercaptopurine	thalidomide
brentuximab vedotin	estramustine	methotrexate <sup>2</sup>	thioguanine
busulfan <sup>2</sup>	etoposide	mitoMYcin	thiotepa
		mitoXANtrone	topotecan
			trametinib
cabazitaxel	floxuridine		
capecitabine <sup>2</sup>	flucytosine	nelarabine	valGANciclovir <sup>2</sup>
CARBOplatin	fludarabine	nilotinib	valrubicin
carmustine	fluorouracil		vandetanib
chlorambucil		oxaliplatin	vemurafenib
CISplatin	ganciclovir		vinBLAStine
cladribine	gefitinib <sup>2</sup>	PACLitaxel	vinCRIStine
clofarabine	gemcitabine	pazopanib	vinorelbine
crizotinib	gemtuzumab ozogamicin	PEMEtrexed	vorinostat
cyclophosphamide		pentostatin	
cytarabine	hydroxyurea	phenoxybenzamine	
		procarbazine <sup>2</sup>	

**SEE PAGE 2 FOR NON-CYTOTOXIC HAZARDOUS MEDICATIONS**

- The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
  - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
  - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec<sup>®</sup> which contains misoprostol and diclofenac).
  - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
  - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
- "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings, 2014* for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

**Revised and Effective February 2016**

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: [http://home.wrha.mb.ca/prog/pharmacy/medications\\_safehandling.php](http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php)

# WRHA HAZARDOUS MEDICATIONS LIST<sup>1</sup>

NON - CYTOTOXIC HAZARDOUS MEDICATIONS		
abiraterone	finasteride <sup>2</sup>	nafarelin
acitretin	fingolimod	nilutamide <sup>2</sup>
alitretinoin	fluoxymesterone <sup>2</sup>	
ambrisentan	flutamide <sup>2</sup>	oxandrolone <sup>2</sup>
anastrozole <sup>2</sup>	foscarnet	
	fulvestrant	pentamidine (aerosol only)
bacillus calmette guerin <sup>3</sup> (bladder instillation only)		podofilox
bexarotene	ganirelix	podophyllum resin
bicalutamide <sup>2</sup>	goserelin	
bosentan		raloxifene <sup>2</sup>
buserelin	iloprost	ribavirin
	ISOtretinoin	
cetorelix	leflunomide <sup>2</sup>	sirolimus
choriogonadotropin alfa	letrozole <sup>2</sup>	tacrolimus
cidofovir	leuprolide	tamoxifen <sup>2</sup>
clomiPHENE		testosterone
colchicine <sup>2</sup>	megestrol <sup>2</sup>	tretinoin
cycloSPORINE	methacholine	trifluridine
cyproterone	methylTESTOSTERone	triptorelin
	mifepristone	
degarelix	misoprostol <sup>2</sup>	
dinoprostone <sup>2</sup>	mitotane	
dutasteride	mycophenolate mofetil	
	mycophenolic acid	
everolimus		
exemestane <sup>2</sup>		

**SEE PAGE 1 FOR CYTOTOXIC HAZARDOUS MEDICATIONS**

- The following groups of products are not listed on the WRHA Cytotoxic and Non-Cytotoxic Hazardous Medications List but require handling precautions.
  - Salts, pegylated and liposomal medications; only the parent compound is listed. Handle all derivatives of a hazardous medication the same as the parent compound.
  - Combination products containing one or more hazardous medications shall be handled as hazardous medications (e.g. Arthrotec<sup>®</sup> which contains misoprostol and diclofenac).
  - Radioactive pharmaceuticals; nuclear medicine has policies and procedure for safe handling of radioactive pharmaceuticals. These products are generally not handled by pharmacy.
  - Chemicals / raw powders; see the Material Safety Data Sheet (MSDS) for safe handling precautions.
- "Dissolve and dose" may be considered as a method of oral administration when a liquid preparation is required.
- Bacillus Calmette Guerin (BCG), when used for bladder instillation, shall be prepared following the instructions provided with the closed system reconstitution kit and in the *Bladder Instillation of Bacillus Calmette-Guerin (BCG) & BCG/Interferon for the Treatment of Bladder Cancer Directive*. See: <http://home.wrha.mb.ca/prog/surgery/files/BCGOPERATIVEDIRECTIVE.pdf>

ACKNOWLEDGEMENT: This list is adapted from the *National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and other Hazardous Drugs in Healthcare Settings*, 2014 for use in WRHA facilities and CancerCare Manitoba.

The list is revised as new medications or information become available.

**Revised and Effective February 2016**

Prepared by WRHA Regional Pharmacy Program, St Boniface Hospital Pharmacy Department and Pharmacy Department, CancerCare Manitoba

For the most recent version of this list go to: [http://home.wrha.mb.ca/prog/pharmacy/medications\\_safehandling.php](http://home.wrha.mb.ca/prog/pharmacy/medications_safehandling.php)